• Novo Nordisk to buy 3 fill-finish sites in $11B deal

    As Novo Nordisk increases the output of its popular weight loss drug Wegovy, the Denmark-based drugmaker agreed to buy three fill-finish manufacturing sites for $11 billion. 
  • How does your system manage rare disease patients? Becker's wants to hear.

    Sponsored
    Fill out this short survey here and attend our annual meeting for free.
  • Yale New Haven to open new pharmacy

    Yale New Haven (Conn.) Health is opening its fourth pharmacy Feb. 6, which will offer home deliveries, according to a news release shared with Becker's. 
  • In 4 months, NYC Health + Hospitals mails 230 abortion kits

    In October, NYC Health + Hospitals became the first public health system in the U.S. to launch telehealth abortion access, which includes medication abortion for eligible patients. 
  • For 1st time in 20 years, US broadens access to methadone

    Flexibilities for the opioid use disorder treatment methadone made during the COVID-19 pandemic have now been made permanent, HHS said Feb. 1, marking the first substantial changes to its regulations in 20 years. 
  • 2 more cancer drug injectables fall into shortage

    Multiple solutions of etoposide and topotecan are on back order.
  • Top 20 pharmacy schools for first-time NAPLEX pass rates

    First-time pass rates for the North American Pharmacist Licensure Examination have slightly dipped in the past two years, according to data from the National Association of Boards of Pharmacy. 
  • Government, pharma companies initiate price talks for 10 of the most expensive drugs

    Feb.1 marks the first day that federal officials will negotiate the price for 10 of the most expensive drugs as part of the Biden administration's Inflation Reduction Act, The Hill reported.
  • What an 'obesity bill of rights' means for medical care amid the rise of weight loss drugs

    Among the rise in popularity of weight-loss drugs, an "obesity bill of rights" has been published and endorsed by nearly 40 national obesity, and chronic disease organizations, with the aim to have providers incorporate the standards into medical practice.
  • ASHP elects 5 leaders to digital, telehealth committee

    On Feb. 1, the American Society of Health-System Pharmacists appointed five leaders to its new digital and telehealth practitioners committee. 
  • Top 15 pharmacy schools by NAPLEX pass rates

    The average all-time pass rate of the North American Pharmacist Licensure Examination was 75.7% in 2023 — a slight increase from the year prior, according to data from the National Association of Boards of Pharmacy. 
  • Clinicians ration penicillin amid syphilis surge

    The spike in syphilis cases across the U.S. are spurring public health agencies to recommend that clinicians ration penicillin injectables, the preferred treatment, KFF Health News reported Feb. 1. 
  • US bulks up access to sickle cell treatments

    As part of its new cell and gene therapy access tool, HHS' first focus is improving access to sickle cell disease therapies, which can cost millions of dollars for a one-time dose. 
  • Biogen abandons controversial Alzheimer's drug Aduhelm

    Biogen is discontinuing its Alzheimer's drug Aduhelm, which was approved in 2021 but became snarled in efficacy concerns and payers' refusals to cover the medication. 
  • Walgreens to lay off more corporate staff

    After laying off 5% of its corporate workforce in November, Walgreens will lay off 145 more workers, most of whom are corporate employees, the company confirmed to Becker's. 
  • 9 drugs now in shortage

    In January, nine more drugs fell into shortage, adding to the 300-some medications in short supply because of manufacturing delays, quality issues or high demand. 
  • Drugmaker recalls ADHD medication over pill mix up

    Azurity Pharmaceuticals has recalled one lot of Zenzedi — a drug used to treat narcolepsy and ADHD — after learning that at least one bottle contained a different drug. 
  • Experimental pain relief drug clears phase 3 metrics

    An experimental drug was produced clinically meaningful pain relief among surgical and non-surgical pain conditions, and the therapy could fill the gap between safe, low-efficacy medicines and opioid treatments, its manufacturer said Jan. 30. 
  • Michigan Medicine makes specialty pharmacy a strategic focus

    As the effects of the COVID-19 pandemic have lessened, officials at Ann Arbor-based Michigan Medicine, which includes University of Michigan Health and the university's medical school, have been able to invest in innovative care, including expanding its specialty and mail-order pharmacy program. Among the goals were increasing the number of prescriptions it fills annually through its in-house pharmacy, as well as reducing the time it takes to fill prescriptions for patients.
  • California system taps specialty pharmacy partner

    Sharp HealthCare, a seven-hospital system in San Diego, partnered with a specialty pharmacy solutions provider Jan. 30.
  • FDA sets end date for Paxlovid emergency use

    The FDA will end emergency use authorization of Paxlovid for adult patients March 8. 

Featured Whitepapers

Featured Webinars

>